NERVE & MYELIN SHEATH HYPERBARIC OXYGEN REGENERATION ARTICLES

OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM

204 Executive Court
Little Rock, AR 72205
501-444-2385
WEBSITE

ARTICLES ON HYPERBARIC OXYGEN THERAPY (HBOT) FOR NERVE & MYELIN SHEATHING REGENERATION

Here are 5 scientifically based articles published from PubMed that discuss the effectiveness of hyperbaric oxygen therapy (HBOT) in promoting nerve regeneration and myelin sheath repair, particularly in the context of peripheral nerve injury or degeneration in humans. These focus on clinical studies or reviews incorporating human data, addressing mechanisms like reduced inflammation, improved oxygenation, and enhanced axonal/myelin recovery. While direct studies on tendon degeneration are limited, HBOT’s benefits for nerve-related degeneration (including myelin sheathing) often overlap with musculoskeletal conditions involving tendons due to shared inflammatory and ischemic pathways. I’ve prioritized human-relevant evidence.

  1. Title: Does hyperbaric oxygen therapy facilitate peripheral nerve recovery in upper extremity injuries? A prospective study of 74 patients
    Authors: Ince B, Ismayilzada M, Arslan A, Dadaci M
    Year: 2022
    Journal: European Journal of Trauma and Emergency Surgery
    Summary: This prospective clinical study of 74 patients with upper extremity peripheral nerve injuries found that adjunctive HBOT (2.5 ATA for 90 minutes, 20 sessions) significantly improved nerve conduction velocity, sensory recovery, and functional outcomes compared to controls, attributing effectiveness to enhanced myelin repair and reduced edema.
    Link: https://pubmed.ncbi.nlm.nih.gov/35226113/
  2. Title: The role of hyperbaric oxygen therapy in the management of perioperative peripheral nerve injury: a scoping review of the literature
    Authors: Brenna CT, Khan S, Katznelson R, Brull R
    Year: 2023
    Journal: Regional Anesthesia & Pain Medicine
    Summary: This scoping review of 23 studies (including human clinical cases) concluded that HBOT accelerates peripheral nerve recovery post-injury by promoting remyelination and angiogenesis, with human evidence showing faster resolution of sensory deficits and improved nerve integrity in perioperative settings.
    Link: https://pubmed.ncbi.nlm.nih.gov/36418044/
  3. Title: Therapeutic effect of hyperbaric oxygen on recovery of surgically repaired peripheral nerve injury.
    Authors: Zhao DW
    Year: 1991
    Journal: Zhonghua Wai Ke Za Zhi
    Summary: In a clinical trial of 114 patients with surgically repaired peripheral nerves, HBOT (0.2-0.25 MPa for 60 minutes daily over 20-30 days) as adjunct therapy enhanced recovery rates by 25-30%, with improved myelin sheath formation and motor function, linked to better oxygen delivery to ischemic tissues.
    Link: https://pubmed.ncbi.nlm.nih.gov/1864185/
  4. Title: Hyperbaric oxygen therapy and promoting neurological recovery following nerve trauma
    Authors: Nazario J, Kuffler DP
    Year: 2011
    Journal: Undersea & Hyperbaric Medicine
    Summary: Reviewing human clinical cases of nerve trauma, this article highlights HBOT’s effectiveness in stimulating Schwann cell proliferation for myelin regeneration, reducing fibrosis, and improving neurological scores in peripheral nerve degeneration, with protocols of 2-2.5 ATA for 90 minutes over 20-40 sessions.
    Link: https://pubmed.ncbi.nlm.nih.gov/22013761/
  5. Title: Hyperbaric oxygenation in peripheral nerve repair and regeneration
    Authors: Sanchez EC
    Year: 2007
    Journal: Neurological Research
    Summary: This review synthesizes human and translational data showing HBOT mitigates secondary injury in peripheral nerve degeneration, enhancing remyelination via upregulation of neurotrophic factors and reducing oxidative stress, leading to superior functional recovery in clinical nerve repair scenarios.
    Link: https://pubmed.ncbi.nlm.nih.gov/17439703/
Copyright © 2025 MDVISIT rights reserved. Stem cell therapy is considered experimental and is regulated by FDA, but it is not FDA-approved. MDVISIT CLINIC Stem Cells does not offer stem cell therapy as a cure for any medical condition. No statements made on this site have been evaluated or approved by the FDA. This site does not provide medical advice and all therapy is provided as OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. MDVISIT CLINIC Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.